| Officer | Age | In this role | Source |
|---|---|---|---|
|
Xi-Yong (Sean) Fu
Also a director
Director and Chief Executive Officer
|
54 |
Since 2024
2 years
|
|
|
Srishti Gupta
Chief Executive Officer
Title from the Form 4 dated Jul 6, 2026
|
Not stated | Not stated | |
|
Ming (Kyler) Lei
Chief Financial Officer
|
29 |
Since 2025
1 year
|
|
|
Charles Silberstein
Chief Financial Officer
Title from the Form 3 dated Nov 2, 2026
|
Not stated | Not stated | |
|
Phillip Dennis
Chief Medical Officer
|
63 |
Since 2024
2 years
|
|
|
Liwei (Lorraine) Lin
General Counsel
|
38 |
Since 2026
this year
|
|
|
Mark Arnold Hagler
Chief Commercial Officer
Title from the Form 4 dated Jul 8, 2026
|
Not stated | Not stated | |
|
Cong (Claire) Xu
EVP, Clinical Development
Title from the Form 4 dated Aug 30, 2026
|
41 | Not stated | |
|
Sean Wuxiong Cao
Also a director
Chief Bus. Development Officer
Title from the Form 4 dated Sep 9, 2026
|
59 | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Related-party transactions come from the company’s proxy statement. NovaBridge Biosciences has not filed one with the SEC.
Loading...